<DOC>
	<DOCNO>NCT00209313</DOCNO>
	<brief_summary>The study propose clinical subclinical HSV reactivation associate increase HIV shed mucosal surface , may increase infectiousness HIV-1/HSV-2 coinfected person . To test hypothesis , control HSV reactivation acyclovir , safe medication proven reduce HSV shed , measure HIV level blood , genital , pharyngeal secretion . The study hypothesize acyclovir reduce HIV shed mucosal surface HIV-1/HSV-2 coinfected individual .</brief_summary>
	<brief_title>Usage Acyclovir Suppression HIV-1 HSV-2 Coinfected Persons Cameroon</brief_title>
	<detailed_description>The main objective ass reduction genital HIV-1 shed associate daily acyclovir suppression HSV-2 reactivation . All patient treat usual antibiotic treatment sexually transmit infection diagnose study . In addition , half receive acyclovir 8 week , whilst half receive placebo 8 week . The study medication reverse second 8 week study . The patient attend clinic 3 time per week first last 8 week study every week washout period middle study - total 18 week per participant . At visit genital oral sample collect . A blood sample also collect . For woman participant , pregnancy test perform . The clinic provide pre- post-HIV test counseling .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Coinfection</mesh_term>
	<mesh_term>Acyclovir</mesh_term>
	<criteria>18 year old Documented HIVseropositive HSV2 seropositive determine Focus EIA Not intend move area duration study participation Willing able : 1. provide independent write informed consent 2. undergo clinical evaluation 3. take study drug direct 4. adhere followup schedule Bacterial STDs ( symptomatic STD syndrome laboratoryconfirmed asymptomatic gonorrhea , chlamydia , syphilis ) treat within two week study enrollment random assignment . Women meet follow criterion eligible study . 1 . Known history adverse reaction acyclovir 2 . Planned open label use acyclovir , valacyclovir , famciclovir 3 . Positive pregnancy test 4 . Active opportunistic infection</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2011</verification_date>
	<keyword>HIV-1</keyword>
	<keyword>HSV-2</keyword>
	<keyword>Coinfection</keyword>
	<keyword>Africa</keyword>
	<keyword>Cameroon</keyword>
</DOC>